1. Home
  2. RSSS vs THAR Comparison

RSSS vs THAR Comparison

Compare RSSS & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Research Solutions Inc

RSSS

Research Solutions Inc

HOLD

Current Price

$2.85

Market Cap

97.3M

ML Signal

HOLD

Logo Tharimmune Inc.

THAR

Tharimmune Inc.

HOLD

Current Price

$2.85

Market Cap

90.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RSSS
THAR
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.3M
90.8M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
RSSS
THAR
Price
$2.85
$2.85
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
61.9K
559.0K
Earning Date
02-12-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$49,325,684.00
N/A
Revenue This Year
$4.92
N/A
Revenue Next Year
$7.09
N/A
P/E Ratio
$71.01
N/A
Revenue Growth
5.83
N/A
52 Week Low
$2.32
$0.95
52 Week High
$4.12
$9.08

Technical Indicators

Market Signals
Indicator
RSSS
THAR
Relative Strength Index (RSI) 45.99 52.49
Support Level $2.70 $2.20
Resistance Level $2.97 $3.56
Average True Range (ATR) 0.10 0.24
MACD 0.00 0.04
Stochastic Oscillator 42.92 46.95

Price Performance

Historical Comparison
RSSS
THAR

About RSSS Research Solutions Inc

Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Share on Social Networks: